Vigabatrin Shows No Clear Benefit for TSC Developmental Outcomes
The PREVeNT trial studied the effects of a medication called vigabatrin on infants with Tuberous Sclerosis Complex (TSC), a condition that often leads to epilepsy and developmental challenges.